Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641634) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis' on Dec. 10, 2025.

Brief Summary: The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRO-203 in healthy volunteers and participants with systemic sclerosis.

Participants will be given PRO-203 under the skin (i.e., subcutaneously).

Study Start Date: Oct. 27, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers Systemic Sclerosis (SSc) Scleroderma, Systemic Scleroderma

Intervention: DRUG: PRO-203

PRO-203...